GET DAILY SIGNALSSANUWAVE Health (SNWV) Shares Advance +21% Over 30 Days on Reimbursement Outlook
Key Takeaways
- SNWV shares climbed roughly 21% over the last 30 days, rising from about $4.82 to near $5.84, as the stock rebounded from multi-year lows reached in early September.
- The recovery followed a sharp drawdown that took the stock to a 52-week low of $3.92, with shares still trading far below their 52-week high of $36.20.
- Second-quarter 2026 results showed revenue of $9.74 million (down about 3% year over year) and a net loss, as weaker system sales offset record applicator and consumable demand.
- A proposed CMS rule that would raise hospital outpatient reimbursement for UltraMIST by 14% in 2027 has become a central factor in investor sentiment.
- SANUWAVE withdrew its fiscal 2026 guidance amid reimbursement uncertainty and finalized a credit-agreement waiver with JPMorgan in late October.
- For additional detail, explore the company's Price Targets, Earnings, and Forecast pages.
- To see how algorithmic strategies are positioning across the market, explore Trending AI Robots.
Company Overview for SANUWAVE Health (SNWV)
SANUWAVE Health, Inc. is a medical-device and shockwave-technology company focused on wound care and regenerative medicine. Headquartered in Eden Prairie, Minnesota and founded in 2004, the company develops and commercializes non-invasive ultrasound and acoustic-pressure shockwave systems that are designed to promote tissue repair and regeneration. Its two primary platforms are the UltraMIST system, a non-contact, low-frequency ultrasound therapy cleared by the FDA for treating acute and chronic wounds, and its PACE (Pulsed Acoustic Cellular Expression) devices, marketed under the dermaPACE, orthoPACE, and Profile brands. I follow SNWV largely because of the company's razor-and-blade model, in which a growing installed base of systems drives high-margin, recurring applicator and consumable revenue.
Stock Price Performance: Last 30 Days Versus the Quarter
Over the last 30 days, SNWV has advanced roughly 21%, moving from a closing price of about $4.82 to a recent level near $5.84. The move marks a meaningful recovery after the stock bottomed near $4.00 in early September, just above its 52-week low of $3.92. Volume also picked up during parts of October, consistent with renewed interest in a micro-cap name trading well below its earlier highs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The longer picture remains more muted. Over the last quarter, the stock is still down approximately 7%, having traded around $6.31 in early August before the summer selloff. In other words, the recent 30-day rally has recovered much, but not all, of the ground lost during the third quarter, when the shares retreated from the low-$6 range toward $4.
Factors Behind the Recent 30-Day Advance
Several verified developments coincided with the stock's October-to-early-November advance. First, the shares rebounded from deeply oversold levels after touching multi-year lows in September, a period when small-cap medtech names were broadly pressured. Second, investors have focused on a proposed CMS rule that would increase hospital outpatient reimbursement for UltraMIST by 14% for calendar year 2027, a potential positive for the company's core wound-care business. The final rule was widely expected around early November, putting reimbursement clarity front and center.
Third, on October 28 the company disclosed an amendment and waiver to its credit agreement with JPMorgan Chase as administrative agent, under which lenders waived a fixed charge coverage ratio shortfall for the twelve months ended September 30, 2026. The waiver reduced near-term covenant uncertainty. Finally, the stock's move occurred as the company approached its third-quarter earnings report, which has been estimated for November 6, 2026, encouraging positioning ahead of the release.
Drivers of Performance Over the Last Quarter
The broader quarterly trend was shaped by a difficult second-quarter report and ongoing reimbursement disruption. SANUWAVE's Q2 2026 results, reported in early August, showed revenue of $9.74 million, down about 3% year over year, with system revenue falling roughly 34% to $2.3 million while consumables and applicator revenue rose about 12% to $7.3 million. Management cited used-system cannibalization and industry disruption from CMS reimbursement changes as headwinds, and it withdrew fiscal 2026 guidance pending greater regulatory clarity.
That combination of a guidance withdrawal, softer capital-equipment sales, and uncertainty around the Physician Fee Schedule contributed to the stock's decline through late summer and into September, when shares touched their 52-week low. The October rebound has been driven less by a change in fundamentals and more by the prospect of favorable outpatient reimbursement and reduced covenant risk.
Near-Term Factors to Monitor
Investors monitoring SNWV should watch several near-term factors. The company's third-quarter earnings report, estimated for November 6, 2026, will provide the next read on recurring applicator and consumable growth versus system sales. Equally important is the CMS final rule on 2027 reimbursement, which could materially affect UltraMIST utilization across hospital outpatient and physician-office settings. Published consensus estimates have pointed to third-quarter revenue around $13.75 million, though coverage remains limited.
Beyond earnings, key considerations include whether the company reinstates financial guidance once reimbursement is clarified, the trajectory of the active installed base, and ongoing compliance with its amended credit agreement. As with any micro-cap medical-device stock, liquidity, execution risk, and regulatory exposure remain important considerations.
Using Tickeron Tools for Additional Perspective
In my research process, I frequently reference Tickeron’s AI Trend Prediction Engine to cross-check momentum signals and potential price paths for holdings like SNWV. It provides a concise way to layer quantitative views onto the fundamental and regulatory developments I am already tracking.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for SNWV turns positive, indicating new upward trend
SNWV saw its Momentum Indicator move above the 0 level on October 28, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 128 similar instances where the indicator turned positive. In 113 of the 128 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 54 cases where SNWV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
SNWV moved above its 50-day moving average on October 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SNWV crossed bullishly above the 50-day moving average on October 08, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +3.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNWV advanced for three days, in 160 of 195 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 69 of 83 cases where SNWV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Bearish Trend Analysis
The 10-day RSI Indicator for SNWV moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 12 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Moving Average Convergence Divergence Histogram (MACD) for SNWV turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 66 similar instances when the indicator turned negative. In 64 of the 66 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNWV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SNWV broke above its upper Bollinger Band on October 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.896) is normal, around the industry mean (4.209). P/E Ratio (2.893) is within average values for comparable stocks, (1.433). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.873) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. SNWV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNWV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement